Home  »  Company   »  Xeris Biopharma Holdings Inc. (NASDAQ:XERS) Foreca...

Xeris Biopharma Holdings Inc. (NASDAQ:XERS) Forecast To Rise 74.48% To Reach Consensus Target Price

Xeris Biopharma Holdings Inc. (NASDAQ:XERS) has a beta value of 1.39 and has seen 1.28 million shares traded in the recent trading session. The company, currently valued at $166.15M, closed the recent trade at $1.34 per share which meant it gained $0.07 on the day or 5.12% during that session. The XERS stock price is -136.57% off its 52-week high price of $3.17 and 11.19% above the 52-week low of $1.19. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.67 million shares traded. The 3-month trading volume is 803.74K shares.

The consensus among analysts is that Xeris Biopharma Holdings Inc. (XERS) is a Buy stock at the moment, with a recommendation rating of 1.50. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 4 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.16.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Xeris Biopharma Holdings Inc. (NASDAQ:XERS) trade information

Sporting 5.12% in the green today, the stock has traded in the red over the last five days, with the highest price hit on Tuesday, 11/22/22 when the XERS stock price touched $1.34 or saw a rise of 6.29%. Year-to-date, Xeris Biopharma Holdings Inc. shares have moved -56.66%, while the 5-day performance has seen it change -8.63%. Over the past 30 days, the shares of Xeris Biopharma Holdings Inc. (NASDAQ:XERS) have changed -13.61%. Short interest in the company has seen 6.24 million shares shorted with days to cover at 5.72.

Wall Street analysts have a consensus price target for the stock at $5.25, which means that the shares’ value could jump 74.48% from the levels at last check today. The projected low price target is $4.00 while the price target rests at a high of $6.00. In that case, then, we find that the latest price level in today’s session is -347.76% off the targeted high while a plunge would see the stock gain -198.51% from the levels at last check today.

Xeris Biopharma Holdings Inc. (XERS) estimates and forecasts

Figures show that Xeris Biopharma Holdings Inc. shares have outperformed across the wider relevant industry. The company’s shares have lost -35.20% over the past 6 months, with this year growth rate of 52.60%, compared to 11.30% for the industry. Other than that, the company has, however, increased its growth outlook for the 2022 fiscal year revenue. Growth estimates for the current quarter are 59.00% and 59.50% for the next quarter. Revenue growth from the last financial year stood is estimated to be 116.00%.

3 analysts offering their estimates for the company have set an average revenue estimate of $29.12 million for the current quarter. 3 have an estimated revenue figure of $30.78 million for the next quarter concluding in Dec 2022.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -18.30% over the past 5 years.

XERS Dividends

Xeris Biopharma Holdings Inc. is expected to release its next earnings report between August 03 and August 08 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Xeris Biopharma Holdings Inc. (NASDAQ:XERS)’s Major holders

Insiders own 2.68% of the company shares, while shares held by institutions stand at 47.17% with a share float percentage of 48.47%. Investors are also buoyed by the number of investors in a company, with Xeris Biopharma Holdings Inc. having a total of 149 institutions that hold shares in the company. The top two institutional holders are Stonepine Capital Management, LLC with over 11.65 million shares worth more than $17.94 million. As of Jun 29, 2022, Stonepine Capital Management, LLC held 8.57% of shares outstanding.

The other major institutional holder is Blackrock Inc., with the holding of over 8.01 million shares as of Jun 29, 2022. The firm’s total holdings are worth over $12.33 million and represent 5.89% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. As of Jun 29, 2022, the former fund manager holds about 2.86% shares in the company for having 3.89 million shares of worth $5.98 million while later fund manager owns 2.95 million shares of worth $4.61 million as of Sep 29, 2022, which makes it owner of about 2.17% of company’s outstanding stock.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts